46 results on '"Stecca, Carlos"'
Search Results
2. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials
3. Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
4. PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
5. Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
6. Abstract 14175: Risk of Cardiovascular Disease in Women Who Underwent Salpingo-Oophorectomy to Prevent Hereditary Breast Ovarian Cancer: A Systematic Review and Meta-Analysis
7. Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
8. Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis of randomized controlled trials.
9. Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.
10. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
11. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis.
12. Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature
13. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis.
14. Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials.
15. Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis.
16. A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.
17. The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer
18. Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
19. Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)
20. Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study.
21. sj-docx-1-tam-10.1177_17588359221094879 – Supplemental material for The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
22. Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).
23. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
24. Impact of the COVID-19 pandemic on the wellbeing of international fellows training in hematology/oncology at the Princess Margaret Cancer Centre (PMCC).
25. Identification of characteristics associated with long-term survival in patients with metastatic urothelial carcinoma (mUC) who received durvalumab (D) with or without tremelimumab (T) in clinical studies.
26. Trends over time in survival in patients with urothelial carcinoma in the real-world: A multicenter analysis.
27. The prognostic impact of bone metastasis in urothelial carcinoma treated with first-line platinum-based chemotherapy.
28. Malignant giant cell tumor of the uterus: a case report
29. Metastatic Urothelial Cancer: a rapidly changing treatment landscape
30. Enfortumab Vedotin in urothelial cancer
31. Additional file 4: of Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
32. Advanced Esophageal Neoplasm with Subcutaneous Metastasis
33. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
34. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
35. Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with durvalumab with or without tremelimumab in the DANUBE study
36. Interval between last neoadjuvant chemotherapy and surgery and between surgery and first adjuvant chemotherapy in ovarian cancer patients.
37. PTEN and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC).
38. Homologous recombination deficiency and platinum rechallenge in platinum-resistant ovarian cancer patients.
39. Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis.
40. Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.
41. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.
42. Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.
43. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
44. Advanced Esophageal Neoplasm with Subcutaneous Metastasis
45. Survival and pulmonary function in stage IA non-small cell lung cancer after sublobar resection versus lobectomy: An updated meta-analysis.
46. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.